-
11.13.2025 | Urgent itch? You can order this new STI test on DoorDash
Starting this week, women can order a first-of-its-kind, at-home swab test for three common sexually transmitted infections and have it delivered straight to their door.
-
11.05.2025 | Seres Therapeutics reports third quarter 2025 financial results and provides business updates
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today reported third quarter 2025 financial results and provided business updates.
-
11.01.2025 | Bird flu’s human risk spurs phage therapy research
While bird flu primarily devastates avian populations, its occasional spillover into humans raises concern, not only because of the viral infection itself, but also due to the secondary bacterial infections that often complicate severe influenza cases. This intersection of viral and bacterial disease has renewed attention on bacteriophage therapy—not only as a precision tool to combat opportunistic bacterial pathogens, but also as an innovative platform to develop vaccines against HPAI itself.
-
10.30.2025 | Seres to obtain $3.6m from CARB-X for SER-155 development
In a placebo-controlled, randomised Phase Ib trial, the therapy demonstrated a 77% reduction in bacterial BSIs against placebo.
-
10.28.2025 | Locus Biosciences enters research collaboration to develop precision antibacterial therapies for ophthalmic infections
Locus Biosciences, Inc. a clinical-stage biotechnology company developing precision engineered bacteriophage treatments for a diverse set of bacterial diseases, today announced a research collaboration agreement with Viatris Inc. (NASDAQ: VTRS), a global healthcare company, to develop novel engineered bacteriophage products targeting ophthalmic bacterial infections.
-
10.20.2025 | CF trial completes enrollment, nears top-line results for lung infections
Enrollment has finished in a clinical trial testing the experimental therapy CMTX-101, which is designed to help clear out bacterial lung infections in people with cystic fibrosis (CF) and other diseases.
-
10.20.2025 | Immunotherapy: a new era for the treatment of bacterial infections
Compared to the therapeutic evolution seen in the oncology field, antimicrobial therapeutics is still, after 60 years, only at the early stages.
-
10.16.2025 | Clarametyx Biosciences announces completion of enrollment in Phase 2a study of CMTX-101 in cystic fibrosis
Clarametyx, a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory disease, announced today that it has completed enrollment in its Phase 1b/2a clinical trial evaluating CMTX-101, a novel immune-enabling antibody therapy in development to treat cystic fibrosis (CF)-associated pulmonary biofilm infections.
-
10.16.2025 | Peptilogics raises $78 Million to advance zaloganan into pivotal trial
Peptilogics, a clinical-stage biotechnology company developing transformative surgical therapeutics to effectively treat and prevent serious medical device infections, today announced the completion of an oversubscribed $78 million Series B2 financing round.
-
10.16.2025 | Peptilogics raises millions to fund pivotal trial for prosthetic joint infection treatment
Biotechnology company Peptilogics announced today that it has completed a $78 million financing round to support a phase 2/3 trial of its investigational treatment for prosthetic joint infections (PJIs).
-
10.08.2025 | Fresh off $30M round, Seattle startup Lumen Bioscience adds Microsoft vet Jeff Raikes to board
Seattle-based biotech startup Lumen Bioscience raised a $30 million Series C extension and announced several leadership updates.
-
10.06.2025 | Un cocktail di fagi armati con CRISPR per trattare tumori ematologici
La terapia fagica mira a eliminare i batteri E. coli resistenti nel microbioma di pazienti oncologici, riducendo il rischio di gravi infezioni durante la neutropenia.
-
09.15.2025 | CF Foundation invests over $7M to support phage therapy development
The Cystic Fibrosis Foundation is investing up to €6.5 million (about $7.6 million) to support the development of virus-based therapies to treat Pseudomonas infections in people with cystic fibrosis.
-
09.09.2025 | CF Foundation invests up to €6.5 million in SNIPR Biome to develop engineered phage therapy
SNIPR plans to enhance phages — a type of virus that targets bacteria — to improve their ability to eliminate persistent Pseudomonas infections in people with cystic fibrosis.
-
09.08.2025 | Research Roundup: Urine-based TB test, lower respiratory tract infections test, nasal spray for COVID
CARB-X last week announced that it is awarding $1 million to Zeteo Tech to further work on a rapid, non-invasive diagnostic test that can diagnose lower respiratory tract infections, like pneumonia, using breath samples.
-
09.03.2025 | CARB-X to support lower respiratory tract infection diagnostic by Zeteo
CARB-X has awarded Zeteo Tech, Inc. US$1M to execute a workplan for its noninvasive diagnostic platform that aims to evaluate whether exhaled breath can diagnose lower respiratory tract infections (LRTIs) in high-risk populations within critical care environments, including intubated patients with mechanical ventilation.
-
09.03.2025 | CARB-X awards $1M to Zeteo Tech for breath-based respiratory infection testing
CARB-X on Wednesday said it has awarded Zeteo Tech $1 million to support studies on the use of the company's breath-based testing platform to aid the diagnosis of lower respiratory tract infections.
-
09.03.2025 | CARB-X funds development of novel diagnostic for lower respiratory tract infections
CARB-X announced today that it is awarding $1 million to biotechnology company Zeteo Tech to advance work on a noninvasive diagnostic test that can diagnose lower respiratory tract infections (LRTIs) from exhaled breath.
-
08.29.2025 | CARB-X backs neonatal sepsis diagnostic platform by Quantamatrix
CARB-X has awarded QuantaMatrix Inc. US$2.85M to execute a workplan to develop its rapid diagnostic platform to detect sepsis, especially in vulnerable neonates.
-
08.28.2025 | CARB-X funds work on rapid diagnostic platform for neonatal sepsis
CARB-X announced today that it is awarding $2.85 million to South Korean diagnostics company QuantaMatrix Inc. to advance work on a rapid diagnostic platform for neonatal sepsis.
-
08.28.2025 | QuantaMatrix nabs $2.9M in CARB-X funding to develop neonatal sepsis test
CARB-X on Thursday said it has awarded QuantaMatrix $2.9 million to support the development of a sepsis test for neonates and other patients.
-
08.26.2025 | Debiopharm pushes the boundaries of innovation in antibiotic development against gonorrhea with first-in-human Debio 1453 trial
First participant dosed with Debiopharm’s Debio 1453, a new drug candidate to address the high unmet need of multidrug-resistant infections with Neisseria gonorrhoeae.
-
08.26.2025 | CARB-X awards $1.1 million to phage-based product for E coli bloodstream infections
CARB-X announced today that it is awarding $1.1 million to biotechnology company Phiogen to advance its novel bacteriophage-based treatment and preventive for extraintestinal pathogenic Escherichia coli (ExPEC) bloodstream infections.
-
08.26.2025 | Avails Medical announces first commercial agreement in company history
Avails Medical, Inc., a leader in the development of rapid, automated, and fully electrical antibiotic susceptibility testing (AST) technologies, today announced that it has signed its first U.S. commercial customer, a world renowned academic medical center and flagship hospital for a six-hospital system, for the company's groundbreaking eQUANT™ System.
-
08.25.2025 | Baxiva sichert sich 3 Millionen Dollar für Impfstoff gegen Kolibakterium
Baxiva erhält von CARB-X, einer multinationalen Partnerschaft mit Hauptsitz an der Universität Boston, eine Finanzierung von 3 Millionen Dollar.
-
08.22.2025 | $3 million advances vaccine against E. coli infections
Recently, CARB-X awarded Baxiva AG $3 million to develop its multivalent glycoconjugate vaccine to prevent extraintestinal pathogenic Escherichia coli (ExPEC) infections.
-
08.22.2025 | Baxiva secures $3 million to advance antibacterial vaccines
CARB-X has awarded Baxiva US$3M to develop its multivalent glycoconjugate vaccine to prevent extraintestinal pathogenic Escherichia coli (ExPEC) infections.
-
08.21.2025 | CARB-X funds development of vaccine against E coli infections
CARB-X announced today that it is awarding $3 million to Swiss biotechnology start-up Baxiva AG.
-
08.12.2025 | Experienced immunologist as CMO
Immunotherapy company Centauri Therapeutics Ltd, based in Alderley Park, Cheshire, UK, has announced the appointment of Dr Debra Barker as Chief Medical Officer (CMO).
-
08.08.2025 | Dansk biotek-scaleup passerer “afgørende milepæl” med stor serie B-runde
SNIPR BIOME, der er i den kliniske fase med base i København, har rejst 35 millioner euro til at videreudvikle en terapiteknologi rettet mod bakterielle infektioner
-
08.07.2025 | FDA puts CMTX-101 on fast track for treating CF lung infections
The U.S. Food and Drug Administration (FDA) has granted two new designations to CMTX-101, an antibody-based therapy Clarametyx Biosciences is developing to treat bacterial lung infections in people with cystic fibrosis (CF).
-
08.07.2025 | Pearl Diagnostics nabs FDA 510(k) clearance for lung infection test
Johns Hopkins University spinoff Pearl Diagnostics said Wednesday that it has received US Food and Drug Administration 510(k) marketing clearance for a urine-based test used to identify Aspergillus fungal infections.
-
08.07.2025 | Danish biotech company grabs €35 million Series B to develop CRISPR therapies for infections and resistance
SNIPR BIOME, a clinical-stage biotech company based in Copenhagen, has raised €35 million in Series B funding to support the development of its CRISPR-based therapies targeting bacterial infections and antimicrobial resistance.
-
08.06.2025 | Antibiotic resistance kills millions. These Australians have an answer
By 2050, scientists estimate 40 million people will have died from superbugs with antimicrobial resistance, as the prospect of fast-evolving bacteria rendering antibiotics ineffectual has driven pharmaceutical companies away from development.
-
08.06.2025 | FDA fast-tracks antibody treatment targeting bacterial biofilms
Clarametyx Biosciences said this week that its investigational antibody treatment for cystic fibrosis patients plagued by chronic bacterial lung infections will receive priority review and development incentives from the US Food and Drug Administration (FDA).
-
08.06.2025 | Innovation and growth: This is what happens when women in deep tech are given space to succeed as entrepreneurs
When women in deep tech are given the support and space needed to step into leadership positions, the opportunity for innovation is endless. This was exactly the case for trailblazers Bliss Cunningham, a Research Fellow at The Doherty Institute, and Ella Casale, a Project Manager in the McDevitt Lab at the University of Melbourne.
-
08.05.2025 | FDA fast tracks antibody therapy for pulmonary infections including cystic fibrosis
Clarametyx Biosciences announced it had received fast track and qualified infectious disease product (QIDP) designations from the FDA for the company’s investigational antibody therapy CMTX-101.
-
08.01.2025 | The top five emerging microbiome startups following their gut
Fecal microbiota transplantation (FMT) has gained traction in the last few decades and microbiome-based therapeutics are getting ever more precise. These five private companies are harnessing the gut to treat inflammation, infections, and even cancer.
-
07.31.2025 | How Lumen is putting the “farm” in biopharma
Biopharmaceuticals are changing the paradigm of disease and treatment. And while they stand as testaments to human ingenuity and scientific discovery, they’re onerous to develop, manufacture, and commercialize.
-
07.30.2025 | Impulso millonario: Kinvard Bio avanza en la lucha contra infecciones resistentes con apoyo de CARB-X
Con el respaldo de CARB-X, Kinvard Bio se enfoca en superar la resistencia a los antimicrobianos, desarrollando fármacos dirigidos a patógenos de alta prioridad que causan infecciones graves.
-
07.29.2025 | Kinvard Bio secures follow-on CARB-X funding to accelerate development of next-generation antibiotics
Non-dilutive funding advances development of differentiated ribosome-targeting antibiotics for serious, drug-resistant infections with high unmet patient need.
-
07.29.2025 | Biotech Centauri Therapeutics receives £3.8m follow-on funding
Cheshire-headquartered biotech company Centauri Therapeutics has received $5.1m (£3.8m) in funding to support the development of its lead compound.
-
07.29.2025 | Centauri gets $5.1M from CARB-X to advance ABX-01 to human trials
Centauri Therapeutics develops antibody-recruiting immunotherapies using its proprietary Alphamer® platform.
-
07.18.2025 | Resistance is futile
SNIPR Biome declares war on antibiotic resistance.
-
06.30.2025 | Harnessing the immune system to combat antimicrobial resistance
Centauri Therapeutics pioneers an immune-based approach as antimicrobial resistance surges.
-
06.29.2025 | Vaxdyn: vacunas andaluzas para combatir bacterias resistentes
En la vertical de Salud, Vaxdyn ha pasado de la etapa preclínica al umbral de ensayos clínicos humanos.
-
06.23.2025 | ArrePath announces closing of their next financing round and appointment of a new board chair
ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates.
-
06.20.2025 | Fuse lit to new range of diagnostic tests
Fuse Diagnostics in Cambridge has launched Flip – what it calls a revolutionary new range of diagnostic tests that deliver laboratory accuracy in a simple, single-use format for rapid point-of-need pathogen testing across industry.
-
06.20.2025 | First patient dosed in phase 1b trial evaluating SNIPR001
On June 12, 2025, SNIPR Biome announced dosing of the first patient in its phase 1b trial of SNIPR001, a CRISPR-based oral therapy aimed at preventing bloodstream infections from drug-resistant E. coli in patients with hematological cancer undergoing stem-cell transplantation.
-
06.17.2025 | Visby Medical raises $55M to launch at-home women’s sexual health test
Visby Medical announced Tuesday that it has raised about $55 million in a recent financing round with the total potentially reaching $65 million.
-
06.17.2025 | Clarametyx to advance trial of CMTX-101 with DMC approval
The trial is evaluating CMTX-101 as an adjunctive therapy to standard of care antibiotics in individuals with CF.
-
06.16.2025 | Vaxdyn, tecnología española contra la pandemia silenciosa
Vaxdyn fue la ganadora de la vertical de salud del certamen Alhambra Ventures de 2023. Los asistentes al evento se dieron cuenta de que, a pesar de lo difícil que es desarrollar nuevos fármacos y especialmente vacunas, una empresa nacida en Sevilla estaba logrando saltar las barreras para llegar a los ensayos en humanos.
-
06.12.2025 | First cancer patient dosed in CRISPR-armed phage therapy
SNIPR Biome has dosed the first patient in its Phase 1b trial of SNIPR001, a CRISPR-CAS-armed bacteriophage therapy that represents a new frontier in precision antimicrobial treatment.
-
06.10.2025 | Australia’s latest deep tech innovators achieve $33.8m in funding milestones
Australia’s national science agency CSIRO has spotlighted a fresh crop of deep tech innovators as part of its ON Accelerate 9 showcase, held in Melbourne this week.
-
05.30.2025 | Harnessing peptide conjugates strategies for cancer immunotherapy and infectious disease
Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, speaks to Helen Bright, CSO, Centauri Therapeutics, about an immune-stimulating platform that leverages peptide conjugation to enhance immune responses.
-
05.28.2025 | CARB-X grants Debiopharm an additional $12.3 million to advance development of novel antibiotic against gonorrhea
Debiopharm, a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, is honored to share that it was awarded further funding from CARB-X.
-
05.07.2025 | Seres Therapeutics reports first quarter 2025 financial results and provides business updates
In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies
-
05.02.2025 | FDA clears first at-home test for chlamydia, gonorrhea, and trichomoniasis
The US Food and Drug Administration (FDA) recently authorized the first at-home test for chlamydia, gonorrhea, and trichomoniasis.
-
04.23.2025 | Interview: Franz-Werner Haas zur Antibiotika-Krise
Die Schweizer LimmaTech Biologics AG hatte im Frühjahr vermeldet, dass die ersten Teilnehmer einer Phase I-Studie mit LBT-SA7 geimpft wurden – einem multivalenten Impfstoffkandidaten zur Vorbeugung von Haut- und Weichteilinfektionen durch den bakteriellen Erreger Staphylococcus aureus.
-
04.08.2025 | It’s now even easier to test for S.T.I.s
The F.D.A. recently authorized a new home test for three of the most common sexually transmitted infections. Here’s what to know.
-
04.07.2025 | Biotech versus the superbugs
UK-based immunotherapy company Centauri Therapeutics recently unveiled its first clinical candidate in its ABX-01 program, a compound designed to target serious gram-negative bacterial infections in the lung.
-
04.04.2025 | FDA authorizes first at-home test for chlamydia, gonorrhea: What to know
The Food and Drug Administration recently approved the first at-home testTrusted Source for three common sexually transmitted infections and diseases that can be purchased without a prescription.
-
04.02.2025 | New agent inhibits Staphylococcus aureus toxin – hope for pneumonia patients
Pneumonia caused by the bacterium Staphylococcus aureus is one of the most dangerous infections that can occur in hospital. Particularly worrying are multi-resistant strains, against which many antibiotics are no longer effective.
-
04.02.2025 | CARB-X funds development of novel antibiotic against superbugs
CARB-X announced today that it has awarded biotechnology company ArrePath, of Princeton, New Jersey, $3.7 million to execute a Lead Optimization workplan for its first-in-class antibiotic targeting a clinically novel portion of pathogenic bacteria for treating complicated urinary tract infections caused by multidrug-resistant (MDR) Enterobacterales bacteria.
-
04.01.2025 | New agent inhibits Staphylococcus aureus toxin – hope for pneumonia patients
An international research group led by the Helmholtz Centre for Infection Research (HZI) has discovered a promising new drug candidate against severe lung infections caused by the hospital germ Staphylococcus aureus.
-
04.01.2025 | With FDA Authorization, Visby Medical aims to bring molecular STI testing to OTC space
By becoming the first diagnostics developer to achieve regulatory clearance for a fully at-home, over-the-counter molecular test detecting sexually transmitted infections, Visby Medical believes it can pave the way for a new market.
-
03.28.2025 | FDA authorizes Visby Medical at-home MDx test for chlamydia, gonorrhea, trichomoniasis
The US Food and Drug Administration announced Friday that it has authorized an over-the-counter molecular test for chlamydia, gonorrhea, and trichomoniasis detection at home.
-
03.20.2025 | Spin-off da U.Porto recebe investimento de 2 milhões de dólares
Consórcio de investidores CARB-X vai apoiar a Immunethep no desenvolvimento de uma vacina contra infeções invasivas por E.coli.
-
03.20.2025 | Scout Health pursuing point-of-care, home MDx testing using novel multiplexing chemistry
Scout Health is aiming to expand the use of point-of-care molecular testing — perhaps even to consumers' homes — with a novel approach that enables sensitive and specific single-tube multiplexing of isothermal nucleic acid amplification.
-
03.19.2025 | Biotech updates: A first dosing and a setback
LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, launched the Phase 1 clinical trial (NCT06719219) in the U.S. after receiving a Fast Track designation from the U.S. Food and Drug Administration (FDA) in 2024.
-
03.11.2025 | FILA 2025: Emerging Innovators, Bugworks Research, on why 2025 will be a watershed year
With three clinical trials underway, and preparations to integrate more artificial intelligence and machine learning for drug discovery, the company that works towards innovating a novel class of antibiotics and cancer drugs is ready for a crucial year.
-
03.11.2025 | Bugworks: Innovating a novel class of antibiotics, cancer drugs
The founders of Bugworks Research are attempting to bring to market a new class of antibiotics – a first in almost half a century.
-
03.05.2025 | Centauri Therapeutics selects first clinical candidate for immunotherapy against Gram-negative infections
As antibiotic resistance escalates, the urgency for alternative treatments intensifies. Centauri Therapeutics Limited stands at the forefront of this revolution with its groundbreaking ABX-01 program.
-
03.04.2025 | Centauri therapeutics selects first ABX-01 clinical candidate
Centauri Therapeutics Limited has announced the selection of its first clinical candidate for the ABX-01 programme.
-
03.04.2025 | Raleigh firm launches Kinvard Bio to focus on antimicrobial resistance
Kineticos Life Sciences, a Raleigh investment firm, has formed a startup to develop a new generation of antibiotics that can overcome drug-resistant infections.
-
03.04.2025 | Forbes India Leadership Awards 2025: Honoring excellence and innovation
BugWorks Research was recognized for its exceptional innovation in biotechnology. The company’s leadership team, Dr. Anand Anandkumar, Dr. V. Balasubramanium, and Dr. Santanu Datta, emphasized that true innovation is not just about discovery but about creating tangible impact.
-
03.04.2025 | Seres Therapeutics receives feedback from FDA on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) development approach
FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections as of 30 days post HSCT in the next study.
-
02.27.2025 | These portable diagnostics go where labs can’t
Federal funding supports engineer Jeff Wang's work to create affordable devices that expand access to health care, leading to faster diagnosis and better health outcomes.
-
02.25.2025 | CARB-X to fund development of E coli vaccine
CARB-X announced today that it is awarding $2 million to Portuguese biotechnology company Immunethep to develop a vaccine against invasive serotypes of Escherichia coli.
-
02.25.2025 | Harvard startup creating a new class of antibiotics
When penicillin, the first antibiotic approved for widespread use, became available in the 1940s, The New York Times reported it as “the most powerful germ killer ever discovered.”
-
02.24.2025 | Small Harvard start-up launches to fight huge problem of antimicrobial resistance
In the face of growing resistance to common antibiotics the world over, North Carolina biotech Kinvard Bio launched on Monday with a mission to develop next-generation drugs that can combat rising “superbugs.”
-
02.20.2025 | LimmaTech franchit un cap : un vaccin innovant contre Staphylococcus aureus entre en phase clinique
La biotech suisse LimmaTech Biologics franchit une étape majeure dans la lutte contre Staphylococcus aureus (S. aureus) en lançant son premier essai clinique de phase 1 pour son candidat-vaccin LBT-SA7.
-
02.18.2025 | LimmaTech impft erstmals in Phase-1-Studie mit LBT-SA7
LimmaTech Biologics hat in den USA die ersten Teilnehmer einer Phase-1-Studie mit seinem multivalenten Impfstoffkandidaten LBT-SA7 geimpft.
-
02.18.2025 | Investigational Staphylococcus aureus vaccine begins Phase 1 study
Munich, Germany-based LimmaTech Biologics AG, announced yesterday that the first participants of a phase 1 trial have been vaccinated with the company’s multivalent vaccine candidate, LBT-SA7.
-
02.14.2025 | Preventive antimicrobials: A promising solution to antibiotic resistance
The health care industry is at a key juncture in the fight against infections. Antibiotic resistance continues to rise, threatening current medical practice patterns. One potential remedy would benefit patients, providers and payers alike: preventive antimicrobials.
-
02.12.2025 | Rapid diagnostic system to detect neonatal sepsis within hours
Neonatal sepsis is a life-threatening condition caused by bloodstream infections in newborns under 28 days old.
-
02.11.2025 | CARB-X funds rapid test to detect pneumonia from urine samples
CARB-X today announced an award of $1 million to Pearl Diagnostics to develop a low-cost, rapid test to diagnose pneumonia caused by Pseudomonas aeruginosa from urine samples.
-
02.10.2025 | CARB-X awards $3M to AstraDx for neonatal sepsis test development
CARB-X said last week that it is awarding $3 million to diagnostics startup AstraDx to support the development of a rapid test for neonatal sepsis.
-
02.07.2025 | CARB-X funds development of rapid diagnostic test for neonatal sepsis
CARB-X announced yesterday that it is awarding $3 million to diagnostics company AstraDx to develop a rapid diagnostic test for neonatal sepsis.
-
02.07.2025 | Brown University Health pneumonia MDx development offers hint of digital PCR’s potential as IVD tool
A newly funded project at Brown University Health's Rhode Island Hospital aims to create a blood-based pathogen RNA test for pneumonia.
-
02.07.2025 | Brown University Health pneumonia MDx development offers hint of digital PCR’s potential as IVD tool
A newly funded project at Brown University Health's Rhode Island Hospital aims to create a blood-based pathogen RNA test for pneumonia.
-
02.07.2025 | AstraDx receives $3M CARB-X funding for neonatal sepsis test
CARB-X has awarded $3 million to diagnostics company AstraDx to develop a rapid test for neonatal sepsis.
-
02.07.2025 | CARB-X funds development of rapid diagnostic test for neonatal sepsis
CARB-X announced yesterday that it is awarding $3 million to diagnostics company AstraDx to develop a rapid diagnostic test for neonatal sepsis.
-
02.03.2025 | Rhode Island Hospital advances pneumonia diagnosis with rapid blood test study
When it comes to pneumonia, it could take a few days to figure out if it's viral or bacterial to best determine how to treat it. New research promises to change that.
-
01.31.2025 | Novel test to diagnose bacterial pneumonia directly from whole blood
One of the major challenges in diagnosing pneumonia is the difficulty in obtaining an appropriate sample, and frequently, no pathogen is identified.
-
01.30.2025 | Nowe finansowanie dla terapii CMTX-101 – nadzieja na skuteczniejsze leczenie infekcji płuc w mukowiscydozie
Firma Clarametyx Biosciences, specjalizująca się w innowacyjnych terapiach przeciwbakteryjnych, otrzymała wsparcie finansowe od funduszu Kineticos AMR Accelerator Fund (KAMRA Fund).
-
01.30.2025 | Clarametyx Biosciences receives investment from Kineticos AMR Accelerator Fund
Clarametyx Biosciences, a Columbus, OH-based clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, received an investment from Kinetics AMR Accelerator Fund.
-
01.30.2025 | Investment to support CMTX-101 testing for chronic lung infections
Clarametyx Biosciences has announced an investment from Kineticos AMR Accelerator Fund to support the development of CMTX-101, a non-antibiotic treatment candidate for persistent bacterial lung infections in people with cystic fibrosis.
-
01.29.2025 | Neues Antibiotikum wird in Gießen entwickelt
Die Naturstoff-Forschungsgruppe der Justus-Liebig-Universität Gießen erhält rund 950 000 Euro von der Initiative CARB-X.
-
01.29.2025 | Gießen im Kampf gegen Resistenzen: Neues Antibiotikum in Entwicklung!
Die Naturstoff-Forschungsgruppe der Justus-Liebig-Universität Gießen erhält rund 950.000 Euro von der Initiative CARB-X zur Entwicklung eines neuartigen Antibiotikums.
-
01.28.2025 | CARB-X funds Rhode Island Hospital to assess feasibility of direct from blood detection of bacterial pneumonia
CARB-X will award Rhode Island Hospital at Brown University Health US$1M to demonstrate proof-of-concept of a polymerase chain reaction (PCR) approach informed by RNA sequencing to detect bacterial pneumonia directly from whole blood.
-
01.28.2025 | Rhode Island Hospital wins $1M from CARB-X for molecular pneumonia blood test
CARB-X announced Tuesday that it has awarded $1 million to Rhode Island Hospital at Brown University Health to support proof-of-concept studies of a direct-from-blood PCR test informed by RNA sequencing to detect pneumonia-causing bacteria.
-
01.28.2025 | Rhode Island Hospital wins $1M from CARB-X for molecular pneumonia blood test
CARB-X announced Tuesday that it has awarded $1 million to Rhode Island Hospital at Brown University Health to support proof-of-concept studies of a direct-from-blood PCR test informed by RNA sequencing to detect pneumonia-causing bacteria.
-
01.28.2025 | CARB-X funds development of novel pneumonia diagnostic
CARB-X announced today that it is awarding $1 million to Rhode Island Hospital at Brown University Health to develop a test to diagnose bacterial pneumonia from whole blood.
-
01.23.2025 | Vedanta Biosciences publishes additional phase 2 VE303 results in Nature Medicine
VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms. Analyses identified predictors of VE303 colonization and protection from CDI recurrence. Topline data for the ongoing Phase 3 pivotal RESTORATiVE303 study are expected in 2026.
-
01.23.2025 | CARB-X funds development of monoclonal antibody for Staph aureus
CARB-X announced today that it is awarding $729,000 to Chicago-based biotechnology company Immunartes to develop a monoclonal antibody designed to prevent Staphylococcus aureus infections.
-
01.23.2025 | Debiopharm et GARDP signent un accord pour lutter contre l’antibiorésistance
L’entreprise pharmaceutique vaudoise et l’organisation basée à Genève ont annoncé un partenariat pour soutenir le développement d’un nouvel antibiotique contre la gonorrhée.
-
01.21.2025 | Mehr Geld für Antibiotikaforschung in Gießen
Die Justus-Liebig-Universität Gießen (JLU) erhält von der Initiative CARB-X rund 950.000 Euro in der ersten Förderrunde für die Entwicklung von Molekülen zur Hemmung eines spezifischen Proteins gramnegativer Bakterien.
-
01.17.2025 | CARB-X funds peptide antibiotic
CARB-X announced yesterday that it is awarding $610,000 to Justus Liebig University Giessen in Germany to develop a first-in-class peptide antibiotic.
-
01.15.2025 | Visby Medical secures additional $3.9M from CARB-X to fight antibiotic resistance with PCR-based mutation detection at the POC
Visby Medical, a leading innovator in rapid PCR diagnostics, has secured an additional $3.9 million from CARB-X to accelerate its fight against antibiotic resistance.
-
01.14.2025 | Nationwide Children’s spinoff targeting antibiotic resistance starts developing vaccine
A Nationwide Children's Hospital spinoff is developing a vaccine based on the same biotechnology it's testing as an antibody treatment attacking chronic drug-resistant infections.
-
01.14.2025 | Swiss-based non-profit GARDP supports the development of Debiopharm’s new potential treatment for gonorrhoea
The Global Antibiotic Research & Development Partnership (GARDP) and the Swiss-based global biopharmaceutical company Debiopharm have signed a memorandum of understanding to develop Debio 1453, a novel compound representing a new antibiotic class that targets Neisseria gonorrhoeae.
-
01.14.2025 | CARB-X grants Melio $3.5M for neonatal sepsis rest, Visby wins additional $3.9M
CARB-X announced Tuesday that it will fund diagnostics firm Melio $3.5 million to develop a rapid assay for the detection of neonatal sepsis. In a separate announcement on Wednesday, Visby Medical announced that it has received $3.9 million in additional funding from CARB-X to support its point-of-care gonorrhea assay using instrument-free PCR.
-
01.14.2025 | CARB-X funds rapid diagnostic test platform for bloodstream infections
CARB-X today announced an award of $3.5 million to biotechnology company Melio to develop a rapid diagnostic test for bloodstream infections, including neonatal sepsis.
-
01.14.2025 | CARB-X funds Melio to develop rapid diagnostic to detect neonatal sepsis
CARB-X will award biotechnology company Melio US$3.5M to develop and execute a technical feasibility workplan for its culture-free platform designed to identify blood stream infections including neonatal sepsis.
-
01.10.2025 | Peptilogics receives $3.3 million from CARB-X to develop treatment for fracture-related infections
CARB-X yesterday announced an award of $3.3 million to Pittsburgh-based Peptilogics to develop a slow-release version of its investigational, broad-spectrum therapeutic for joint-related infections.
-
01.09.2025 | CARB-X funds Peptilogics to develop a novel, broad-spectrum therapeutic to treat fracture-related infections
CARB-X will award Peptilogics US$3.3 million to develop and execute a workplan for its slow-release formulation of a novel, broad-spectrum therapeutic, zaloganan-CR, an engineered peptide intended for use in preventing infection after high-energy-traumatic bone injuries.
-
01.09.2025 | Seres Therapeutics announces new translational biomarker results from SER-155 Phase 1b clinical study and provides corporate updates
Seres Therapeutics, a leading live biotherapeutics company, today announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b placebo-controlled study in patients undergoing allogenic stem cell transplantation (allo-HSCT).
-
01.08.2025 | Basilea provides portfolio update and outlook
Basilea Pharmaceutica Ltd, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today on the progress of its Research & Development portfolio in 2024 and upcoming milestones.
Toggle navigation